Axatilimab Plus Ruxolitinib May Be a Safe Combination Against Newly Diagnosed GVHD - Hematology Advisor Researchers sought to determine whether combining axatilimab and ruxolitinib is a safe strategy among patients with newly diagnosed chronic GVHD.

REVEAL study: Axatilimab + ruxolitinib achieved 69% ORR in R/R #cGvHD. 🩺

60% of patients reported ≥1 Grade 3 TEAE.

20.5% experienced Grade 4.

Findings from #Tandem26 via @astct.bsky.social @cibmtr.bsky.social

Read the review: https://bit.ly/4cyLJ9o

#Hematology #GvHD #MedicalNews

Post-Transplantation Cyclophosphamide May Reduce Chronic GVHD Risk Compared With MMF Combining post-transplantation cyclophosphamide with sirolimus and cyclosporine appears to reduce the incidence of cGVHD compared with sirolimus, cyclosporine, and MMF.

Combining post-transplantation cyclophosphamide with sirolimus and cyclosporine appears to reduce the incidence of #cGVHD compared with sirolimus, cyclosporine, and MMF. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/48VJZnn

#GVHD

Rezurock 200 mg Tablet Buy Online - India, USA, UK, UAE Rezurock 200 mg Tablet contains Belumosudil, FDA-approved for treating chronic graft-versus-host disease (cGVHD) in patients aged 12 years and older after prior systemic therapies.

Rezurock 200 mg Tablet contains Belumosudil, prescribed for chronic graft-versus-host disease (cGVHD) in patients 12 years and older who did not respond to prior treatments.
#rezurock #belumosudil #cgvhd #belumosudil200 #rezurock200

www.drugsgeneral.com/rezurock-200...

Heading to #WTC2025? See Joe Douglas presenting in Abstract Session RF01.1 – Fundamentals of Transplantation Science. 🗓️ SUN 8/3 🕖 7-8am PDT 📍 Room 12

Use of BMT CTN 1202 Samples to Develop an Algorithm for Prediction & Diagnosis of cGvHD for Peripheral Blood HCT Recipients.

🔗 LINKS 👇

#cGvHD #BMT

Orca Bio’s T-cell therapy shows promise in haematological malignancies - PharmaTimes The company is preparing to submit the results to the FDA this year

#OrcaBio #allogeneiccelltherapy #OrcaT #Tcelltherapy #investigationalallogeneicTcellimmunotherapy #PrecisionTtrial #acutemyeloidleukaemia #acutelymphoblasticleukaemia #highriskmyelodysplasticsyndrome #mixedphenotypeacuteleukaemia #alloHSCT #cGvHD #alloHSCT
pharmatimes.com/news/orca-bi...

Fred Hutch at #Tandem25: Dr. Masumi Ueda Oshima to present results of a novel drug regimen that shows great promise in preventing #cGVHD after transplant in people who received nonmyeloablative or reduced-intensity conditioning to treat a blood cancer. bit.ly/411oqO2

Abbisko's Pimicotinib Shows Promise in Treating Chronic Graft-versus-Host Disease at ASH 2024 Abbisko Therapeutics revealed promising results from its Phase 2 study of pimicotinib for chronic Graft-versus-Host Disease at ASH 2024. The data suggests significant clinical efficacy.

Abbisko's Pimicotinib Shows Promise in Treating Chronic Graft-versus-Host Disease at ASH 2024 #China #Shanghai #Abbisko #Pimicotinib #cGvHD

A somewhat obscure chronic illness #cGvHD or GvHD chronic Graft vs Host Disorder - a complication of bone marrow/stem cell transplant. Thanks!